1Hughes RA, Charhon J, Latinovic R, et al. No association between immunization and Guillain-Barre syndrome in the United Kingdom, 1992 to 2000. Arch Intern Med, 2006, 166(12) : 1301-1304.
2Raphael JC, Chevret S, Hughes RAC, et al. Plasma exchange for Guillain-Barre syndrome. Cochrane Database Syst Rev, 2007, 3: CD001798.
3Hughes RA, Wijdicks EF, Barohn R, et al. Practice parameter: immunotherapy for Guillain-Barro syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. National Guideline Clearinghouse, 2004, 26: 4110-4114.
5Korinthenberg R, Schessl J, Kirschner J, et al. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barre syndrome : a randomized trial. Pediatrics, 2005, 116(1): 8-14.
6Overell JR, Hsieh ST, Odaka M, et al. Treatment for Fisher syndrome, Bickerstaff's brainstem encephalitis and related disorders. Coehrane Database Syst Rev, 2007 , 3 : CD004761.
7Hughes RAC, Swan AV, van Koningsveld R, et al. Corticosteroids for Guillain-Barre syndrome. Cochrane Database Syst Rev, 2007, 3: CD001446.
8Van Koningsveld R, Schmitz PI, Meche FG, et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome: randomised trial. Lancet, 2004 , 363 ( 9404 ) : 192-196.
9Garssen MP, Schmitz PI, Merkies IS, et al. Amantadine for treatment of fatigue in Guillain-Barre syndrome: a randomised, double blind, placebo controlled, crossover trial. J Neurol Neurosurg Psychiatry, 2006, 77 ( 1 ) : 61-65.
